ChromaDex (CDXC) Stock Plunges 3.81% As It Appeals A Judge’s Decision In A Patent Infringement Lawsuit

The stock market of biotechnology company experiences a slight decrease of 3.81%. Today, ChromaDex (CDXC) crossed a new value of $6.71. Still, weekly statistics show a sharp decline of 13.26%. ChromaDex stated today that it would appeal a September 14 judgment in the United States District Court for the District of Delaware granting a Motion for Summary Judgment in its patent infringement case against Elysium Health. The Trustees of Dartmouth College have licensed ChromaDex U.S. Patent and U.S. Patent, giving the company exclusive rights to the leading NAD precursor nicotinamide riboside.

ChromaDex’s intellectual property portfolio for nicotinamide riboside is robust and expanding, with over 20 compositions, process, and method of use patents for NR and other NAD+ precursor discoveries. Niagen® from ChromaDex is backed by 13 peer-reviewed clinical studies. The U.S. The Food and Drug Administration (FDA), Health Canada, the European Commission, and the Therapeutic Goods Administration (TGA) of Australia have all given their approval to Niagen.

Miriam Bozini

Finance and Business Reporter